Objectives: To compare plasma antiretroviral concentrations in HIV-HCV co-infected and in matched HIV mono-infected patients.
Introduction
HIV and hepatitis C virus (HCV) share common routes of transmission. In Europe and the USA almost 30% of HIV-infected patients are chronically co-infected with HCV. 1, 2 Highly active antiretroviral therapy (HAART) has led to a dramatic decrease in AIDS-related mortality and morbidity, thus liver end-stage related disease is now the most common cause of death in such patients. 3 HAART is associated with a slower progression to fibrosis in HCV co-infected patients. 4 HAART-related toxicity is higher in HIV-HCV co-infected patients compared with HIV mono-infected patients. 5 HAARTrelated liver injury might be attributable to intrinsic antiretroviral drug toxicity, 6 mitochondrial toxicity 7 or immuno-allergic mechanisms. 8 Most antiretroviral drugs are metabolized by the hepatic cytochrome P (CYP) 450 enzyme system; thus, any hepatic disease, including chronic HCV, might impair this metabolism, leading to an increased risk of toxicity. 9 HAART-related side effects may lead to suboptimal adherence and subsequent # The Author 2010. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org J Antimicrob Chemother 2010; 65: 2445 -2449 doi:10.1093/jac/dkq320 Advance Access publication 2 September 2010 therapeutic failure. Therefore, studying antiretroviral drug pharmacokinetics in HIV-HCV co-infected patients might help to identify those with drug concentrations above the expected therapeutic range, which may be helpful in the therapeutic management of these patients.
Our objective was to compare trough concentrations of antiretroviral drugs in HIV-HCV co-infected patients having a documented liver histological fibrosis stage with HIV mono-infected patients. The antiretroviral drugs studied were from the three most common classes: nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs).
Patients and methods

Patients
HEPADOSE was a cross-sectional, observational, monocentre, pilot study conducted in the HIV outpatient unit of Pitié-Salpêtrière Hospital in Paris. All HIV-HCV co-infected patients with a previous liver biopsy who were followed up between September 2002 and February 2004 were invited to participate in this study. Patients had to be receiving a stable antiretroviral treatment regimen for at least 3 months prior to study entry. Participation in the study was also offered to HIV mono-infected patients matched by gender and antiretroviral treatment. HIV-HCV co-infected patients receiving stable antiretroviral combination therapy were compared with HIV mono-infected patients matched by gender and antiretroviral drug administration. HIV mono-infected controls were randomly selected according to gender and antiretroviral status, regardless of clinical status. Twice weekly, the name-list of all patients having an appointment on those two specific days was extracted and their antiretroviral treatment was recorded. A randomized selection was performed among these patients and randomly selected patients were then offered participation in the study, and those who agreed were subsequently included. Patients receiving concomitant medication with known interactions with CYP450 were excluded. For each patient, one measurement for a trough concentration was performed on plasma samples obtained in the morning, approximately 12 h after the last dose was taken. Co-infected patients were included with active HCV infection (positive HCV-RNA) who might previously have undergone HCV treatment. Fibrosis (Fibrotest-Actitest w10 ) was measured in co-infected patients at the time of inclusion in order to get the most recent evaluation of liver injury. Co-infected patients with concordant results of histological and biochemical evaluation of liver injury were included in the analysis. On inclusion, patients were asked to report any potential drug-related side effect (xerosis, lipoatrophy, lipohypertrophy, insomnia, dizziness, mood disorders, diarrhoea, abdominal pain) and their alcohol consumption.
The study was approved by the Ethics Committee of Pitié-Salpêtrière Hospital, and all patients provided written informed consent.
Plasma concentration measurement
For each patient, one measurement of trough plasma concentration for PIs, nucleoside analogues and non-nucleoside analogues was performed on samples collected approximately 12 h after last drug intake and before the morning dose. No dose adjustment following the drug measurement was performed. After liquid or solid phase extraction, plasma concentrations of the NRTI, NNRTI and PI were determined using HPLC coupled with either spectrofluorometric or ultraviolet detection as previously described. 11 All the different methods were linear and validated over the concentration ranges for the different components. Adequate therapeutic concentrations were those used in the GigHAART trial. 11 
Statistical analysis
Comparisons of trough concentrations between groups of patients were performed using a Wilcoxon rank sum test for each antiretroviral drug measured for at least five patients for each drug evaluated. Qualitative data were analysed using Fisher's exact test.
Results
A total of 146 patients were screened and 139 patients were included in the analyses (73 HIV-HCV co-infected patients and 66 HIV-infected patients). Reasons for exclusion included undetectable trough concentrations in three patients with selfreported poor adherence, no pharmacological measurements in three patients and unexplained severe fibrosis in one HIV mono-infected patient (F4 by Fibrotest-Actitest w ). Baseline characteristics and antiretroviral combinations of the 139 patients are summarized in Table 1 . Patients in both groups were well balanced, especially regarding age, alcohol consumption and body mass index. Patients in both groups were receiving antiretroviral therapy; the HIV-HCV co-infected and HIV mono-infected patients had median CD4 cell counts of 334 and 378/mm 3 , respectively, and 67% and 85% had plasma HIV-RNA , 200 copies/mL (P ¼ 0.07). Among coinfected patients, the current regimen was a PI-containing regimen for 64%, an NNRTI-containing regimen for 24%, an NRTI-only regimen for 4% and other combinations for 8%; for HIV mono-infected patients, the corresponding proportions were 62%, 26%, 6% and 6%. Clinical drug-related adverse events (.grade 2), were reported more frequently in the co-infected group (47%) than in the control group (27%, P ¼ 0.02), but lipohypertrophy was significantly less reported in co-infected than in mono-infected patients (4% versus 24%, P, 0.001).
Of the 73 co-infected patients, 56% were infected with HCV genotype 1, 25% with genotype 3 and 19% with genotype 4. Over half of the co-infected patients had been previously treated for HCV infection at inclusion. Using the Fibrotest-Actitest w , 57 (78%) HIV-HCV co-infected patients were scored F2 -F4, of whom 27 (37%) were scored F4. As expected, biochemical markers such as aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, alkaline phosphatase, total bilirubin and a2 macroglobulin were higher among co-infected patients.
Antiretroviral drug plasma trough concentrations
Trough antiretroviral concentrations are summarized in Table 2 .
For PIs, there was no significant difference for indinavir, saquinavir, amprenavir and low-dose ritonavir. In contrast, lopinavir concentrations were significantly lower in the co-infected group (P ¼ 0.04) and tended to inversely correlate with liver fibrosis score (P ¼ 0.08), whereas nelfinavir concentrations were significantly higher in the co-infected group (P ¼ 0.01).There was no difference in the proportions of co-infected and mono-infected patients who had high concentrations of PIs (10/62 co-infected versus 10/45 HIV mono-infected patients).
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Efavirenz trough concentrations were significantly higher in the co-infected patients compared with the mono-infected patients (3583 ng/mL versus 1494 ng/mL, respectively, P ¼ 0.025). The same trend was observed for nevirapine, although the difference did not reach statistical significance. Moreover, 83% of the co-infected patients had high concentrations of efavirenz (.3000 ng/mL) compared with 25% of HIV mono-infected patients. Four out of five co-infected patients with cirrhosis had high concentrations of nevirapine .6000 ng/mL. Overall, there was a greater proportion of co-infected patients with high concentrations of both NNRTIs (15/23) compared with HIV mono-infected patients (5/21) (P ¼ 0.008), especially in co-infected patients with an advanced liver fibrosis stage.
For the NRTIs, abacavir was the only antiretroviral drug with a significant difference in plasma trough concentration between the two groups [median 50 ng/mL in co-infected patients versus 28 ng/mL in HIV mono-infected patients (P ¼0.02)].
Discussion
We show that clinical drug-related adverse events (.grade 2) were reported in a significantly greater proportion of HCV-HIV co-infected patients than of matched HIV mono-infected patients. Co-infected patients have been shown to have significantly reduced CYP3A4 and CYP2D6 activity, 12 possibly resulting in increased drug exposure, 13 which typically correlates with an increase in adverse events. 14 -16 We found that nelfinavir, abacavir and efavirenz concentrations were significantly higher in co-infected patients than in HIV mono-infected ones. Nevirapine concentrations also followed the same trend, but without reaching significance. Our results are in keeping with studies of Katsounas et al., 17 de Requena et al. 18 and Regazzi et al. 19 Conversely, we showed that lopinavir concentrations were significantly lower in HIV-HCV co-infected patients than in HIV mono-infected ones. Conflicting results have been published regarding lopinavir concentrations in HIV-HCV co-infected patients. Peng et al. 20 found significantly higher concentrations of lopinavir in HIV-HCV co-infected patients than HIV mono-infected patients. Canta et al. 21 and Gonzalez de Requena et al. 22 found no significant differences in lopinavir concentrations between HIV-HCV co-infected and HIV mono-infected patients. These discrepancies stress the importance of therapeutic drug monitoring in HIV-HCV co-infected patients. Nelfinavir is metabolized by CYP2C19 (in addition to 3A4 and 2D6), efavirenz is metabolized by CYP2B6 (and CYP3A4) and abacavir is metabolized by alcohol dehydrogenase. It is interesting that CYP3A4 is not the primary metabolic pathway for the three drugs whose concentrations were elevated in the co-infected group. This finding suggests that liver toxicity (i.e. fibrosis etc.) impacts certain CYP pathways before others. Liver fibrosis and antiretroviral concentrations 2447 JAC Overall our study shows that PIs are well tolerated in HIV-HCV co-infected patients due to the absence of major differences in trough concentration between co-infected and mono-infected patients. Conversely, NNRTIs yielded a marked increase in drug intolerance due to significantly higher concentrations in co-infected patients.
Limitations of our study include the small sample size for each antiretroviral drug, unknown substance abuse status 23 and the cross-sectional design of the study. Also, the antiretroviral dose the night before was not observed and patients were relied upon to provide this information. Several pharmacological measurements per patient or calculation of exposure to antiretroviral would have been more appropriate, but such studies are difficult to conduct with a large number of patients. Thus, we were not able to demonstrate significant correlation between elevated drug concentrations and liver injury. This has been previously shown in multiple studies. 24 -28 Therefore, we did not demonstrate the potential negative impact of high concentrations of antiretrovirals on the progression of liver disease in HIV-HCV co-infected patients. Our results suggest that therapeutic drug monitoring is warranted in HIV-HCV co-infected patients, especially with regard to the recent commercialization of new PIs such as darunavir and atazanavir, and secondgeneration NNRTIs such as etravirine and rilpivirine. Further longitudinal studies are needed to assess the role of high concentrations of antiretroviral drugs in HIV-HCV coinfected patients, and the potential impact of dosage adjustment on liver disease progression.
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